1921
Volume 88, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Meglumine antimoniate (Glucantime) remains the therapeutic cornerstone of visceral leishmaniasis (VL). Twenty-one VL patients were treated with Glucantime, extending for 1 week after defervescence. For monitoring the response, kinetoplast DNA loads were evaluated using real-time polymerase chain reaction (PCR) assay in the blood. The maximum duration of treatment was 14 days. The loads before treatment ranged from 8 to 1,300,000 parasites/mL (mean = 73,095 parasites/mL), and the mean values on days 3, 7, 14, 28, and 90 were 4,902, 506, 6.33, 0.26, and 0.14, respectively. The loads decline to < 1 parasite/mL for 16 (76%) and 20 (95%) patients on days 14 and 28, respectively, and they decline for all patients by day 90. Results showed a dramatic decrease of the parasite loads, although complete clearance was not accomplished at the end of treatment. Only one relapse (4.5%) was observed. The parasite load can also serve as a dependable index for monitoring the response to Glucantime.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.12-0440
2013-05-01
2018-12-12
Loading full text...

Full text loading...

/deliver/fulltext/14761645/88/5/868.html?itemId=/content/journals/10.4269/ajtmh.12-0440&mimeType=html&fmt=ahah

References

  1. WHO, 2010. Control of the leishmaniasis. Proceedings of a meeting of the WHO Expert Committee on the Control of Leishmaniases, March 22–26, 2010, Geneva, Switzerland. [Google Scholar]
  2. Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M, WHO Leishmaniasis Control Team; , 2012. Leishmaniasis worldwide and global estimates of its incidence. PLoS ONE 7: e35671.[Crossref] [Google Scholar]
  3. Alborzi A, Rasouli M, Shamsizadeh A, , 2006. Leishmania tropica-isolated patient with visceral leishmaniasis in southern Iran. Am J Med Hyg 74: 306307. [Google Scholar]
  4. Murray HW, Berman JD, Davies CR, Saravia NG, , 2005. Advances in leishmaniasis. Lancet 366: 15611577.[Crossref] [Google Scholar]
  5. Gradoni L, Soteriadou K, Louzir H, Dakkak A, Toz SO, Jaffe C, Dedet JP, Campino L, Cañavate C, Dujardin JC, , 2008. Drug regimens for visceral leishmaniasis in Mediterranean countries. Trop Med Int Health 13: 12721276.[Crossref] [Google Scholar]
  6. Karimi A, Alborzi A, Mahmoodi MR, Rakhshani AH, Kadivar MR, , 1998. Short course anti-Leishmania therapy in children with visceral leishmaniasis. Iran J Med Sci 23: 610. [Google Scholar]
  7. Shahian M, Alborzi A, , 2009. Effect of meglumine antimoniate on the pancreas during treatment of visceral leishmaniasis in children. Med Sci Monit 15: 290293. [Google Scholar]
  8. Alborzi A, Rasouli M, Nademi Z, Kadivar MR, Pourabbas B, , 2006. Evaluation of rK39 strip test for the diagnosis of visceral leishmaniasis in infants. East Mediterr Health J 12: 294299. [Google Scholar]
  9. Aoun K, Chouihi E, Amri F, Ben Alaya N, Raies A, Mary C, Bouratbine A, , 2009. Short report: contribution of quantitative real-time polymerase chain reaction to follow-up of visceral leishmaniasis patients treated with meglumine antimoniate. Am J Trop Med Hyg 81: 10041006.[Crossref] [Google Scholar]
  10. Mary C, Faraut F, Lascombe L, Dumon H, , 2004. Quantitifications of Leishmania infantum DNA by real-time PCR assay with high sensitivity. J Clin Microbiol 42: 52495255.[Crossref] [Google Scholar]
  11. Mary C, Faraut F, Drogoul MP, Xeridat B, Schleinitz N, Cuisenier B, Dumon H, , 2006. Reference values for Leishmania infantum parasitaemia in different clinical presentations: quantitative PCR for therapeutic monitoring and patient follow-up. Am J Trop Med Hyg 75: 858863. [Google Scholar]
  12. Sudarshan M, Weirather JL, Wilson ME, Sundar S, , 2011. Study of parasite kinetics with antileishmanial drugs using real-time quantitative PCR in Indian visceral leishmaniasis. J Antimicrob Chemother 66: 17511755.[Crossref] [Google Scholar]
  13. Lachaud L, Dereure J, Chabbert E, Reynes J, Mauboussin JM, Oziol E, Dedet JP, Bastien P, , 2000. Optimized PCR using patient blood samples for diagnosis and follow-up of visceral leishmaniasis, with special reference to AIDS patients. J Clin Microbiol 38: 236240. [Google Scholar]
  14. Alborzi A, Pourabbas B, Shahian F, Mardaneh J, Pouladfar GR, Ziyaeyan M, , 2008. Detection of Leishmania infantum kinetoplast DNA in the whole blood of asymptomatic individuals by PCR-ELISA and comparison with other infection markers in endemic areas, southern Iran. Am J Trop Med Hyg 79: 839842. [Google Scholar]
  15. Smyth AJ, Ghosh A, Hassan MQ, Basu D, De Bruijn MH, Adhya S, Mallik KK, Barker DC, , 1992. Rapid and sensitive detection of Leishmania kinetoplast DNA from spleen and blood samples of kala-azar patients. Parasitology 105: 183192.[Crossref] [Google Scholar]
  16. le Fichoux Y, Quaranta JF, Aufeuvre JP, Lelievre A, Marty P, Suffia I, Rousseau D, Kubar J, , 1999. Occurrence of Leishmania infantum parasitemia in asymptomatic blood donors living in an area of endemicity in southern France. J Clin Microbiol 37: 19531957. [Google Scholar]
  17. Tupperwar N, Vineeth V, Rath S, dya T, , 2008. Development of a real-time polymerase chain reaction assay for the quantification of Leishmania species and the monitoring of systemic distribution of the pathogen. Diagn Microbiol Infect Dis 61: 2330.[Crossref] [Google Scholar]
  18. Mondal S, Bhattacharya P, Rahaman M, Ali N, Goswami RP, , 2010. A curative immune profile one week after treatment of Indian kala-azar patients predicts success with a short-course liposomal amphotericin B therapy. PLoS Negl Trop Dis 4: e764.[Crossref] [Google Scholar]
  19. van der Meide W, Guerra J, Schoone G, Farenhorst M, Coelho L, Faber W, Peekel I, Schallig H, , 2008. Comparison between quantitative nucleic acid sequence-based amplification, real-time reverse transcriptase PCR, and real-time PCR for quantification of Leishmania parasites. J Clin Microbiol 46: 7378.[Crossref] [Google Scholar]
  20. Costa CH, Stewart JM, Gomes RB, Garcez LM, Ramos PK, Bozza M, Satoskar A, Dissanayake S, Santos RS, Silva MR, Shaw JJ, David JR, Maguire JH, , 2002. Asymptomatic human carriers of Leishmania chagasi . Am J Trop Med Hyg 66: 334337. [Google Scholar]
  21. Davis AJ, Murray HW, Handman E, , 2004. Drugs against leishmaniasis: a synergy of technology and partnerships. Trends Parasitol 20: 7376.[Crossref] [Google Scholar]
  22. Ghalib HW, Whittle JA, Kubin M, Hashim FA, el-Hassan AM, Grabstein KH, Trinchieri G, Reed SG, , 1995. IL-12 enhances Th1-type responses in human Leishmania donovani infections. J Immunol 154: 46234629. [Google Scholar]
  23. Holaday BJ, Pompeu MM, Jeronimo S, Texeira MJ, Sousa A de A, Vasconcelos AW, Pearson RD, Abrams JS, Locksley RM, , 1993. Potential role for interleukin-10 in the immunosuppression associated with kala azar. J Clin Invest 92: 26262632.[Crossref] [Google Scholar]
  24. Saha S, Mondal S, Ravindran R, Bhowmick S, Modak D, Mallick S, Rahman M, Kar S, Goswami R, Guha SK, Pramanik N, Saha B, Ali N, , 2007. IL-10 and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. J Immunol 179: 55925603.[Crossref] [Google Scholar]
  25. Engwerda CR, Murphy ML, Cotterell SE, Smelt SC, Kaye PM, , 1998. Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani . Eur J Immunol 28: 669680.[Crossref] [Google Scholar]
  26. Theodos CM, Povinelli L, Molina R, Sherry B, Titus RG, , 1991. Role of tumor necrosis factor in macrophage leishmanicidal activity in vitro and resistance to cutaneous leishmaniasis in vivo . Infect Immun 59: 28392842. [Google Scholar]
  27. Haldar AK, Sen P, Roy S, , 2011. Use of antimony in the treatment of leishmaniasis: current status and future directions. Mol Biol Int 1: 571242. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.12-0440
Loading
/content/journals/10.4269/ajtmh.12-0440
Loading

Data & Media loading...

  • Received : 20 Jul 2012
  • Accepted : 06 Jan 2013

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error